Novartis Ag (NVS) Cash & Current Investments (2009 - 2026)

Novartis Ag has reported Cash & Current Investments for 18 years, with the latest figure at $7.7 billion in Q2 2026.

• Quarterly Cash & Current Investments rose 9.86% year-over-year to $7.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.7 billion (up 9.86% YoY) and the FY2025 annual result came in at $11.6 billion, up 3.76% from the prior year.
• Cash & Current Investments grew to $7.7 billion in Q2 2026 per NVS's latest filing, from $7.0 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $18.9 billion in Q4 2022 and troughed at -$17.4 billion in Q2 2022.
• A 5-year average of $6.9 billion and a median of $8.1 billion in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments tumbled 7552.79% in 2022, then jumped 1230.12% in 2023.
• Over 5 years, Cash & Current Investments stood at $18.9 billion in 2022, then sank by 32.64% to $12.8 billion in 2023, then dropped by 9.9% to $11.5 billion in 2024, then grew by 0.87% to $11.6 billion in 2025, then slumped by 33.65% to $7.7 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $7.7 billion, $7.0 billion, and $11.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.